Aspirin therapy has widely been used to prevent heart attacks for both men and women. But there may be considerable variation between men and women in the effectiveness of aspirin therapy in reducing the risk of heart attacks.
A recent study, conducted by a group of researchers from University of British Columbia, Vancouver and published online in BMC Medicine, indicated that women may be much less responsive to aspirin than men.
By identifying 23 clinical trials, the researchers examined the effectiveness of aspirin therapy in preventing heart attacks for a total of 113,494 participants. The researchers reported that aspirin therapy, when compared to placebo, provided a modest reduction in the risk of non-fatal heart attacks (28 percent), but did not reduce the risk of fatal heart attacks.
However, considerable variation in the effectiveness of aspirin across the trials was noted. It was found that roughly 27 per cent of the total variation in reports of non-fatal heart attacks could actually be explained by the proportion of men and women in the trial.
According to what the researchers had found, studies that included men had the largest risk reduction in non-fatal heart attacks (38 percent), while trials that mostly included women failed to show a significant reduction in the risk of non-fatal heart attack.
Based on the data analyzed, the researchers concluded that aspirin is less efficacious in women for the reduction of heart attacks. They also raised the possibility that women are more susceptible to aspirin resistance.
A recent study, conducted by a group of researchers from University of British Columbia, Vancouver and published online in BMC Medicine, indicated that women may be much less responsive to aspirin than men.
By identifying 23 clinical trials, the researchers examined the effectiveness of aspirin therapy in preventing heart attacks for a total of 113,494 participants. The researchers reported that aspirin therapy, when compared to placebo, provided a modest reduction in the risk of non-fatal heart attacks (28 percent), but did not reduce the risk of fatal heart attacks.
However, considerable variation in the effectiveness of aspirin across the trials was noted. It was found that roughly 27 per cent of the total variation in reports of non-fatal heart attacks could actually be explained by the proportion of men and women in the trial.
According to what the researchers had found, studies that included men had the largest risk reduction in non-fatal heart attacks (38 percent), while trials that mostly included women failed to show a significant reduction in the risk of non-fatal heart attack.
Based on the data analyzed, the researchers concluded that aspirin is less efficacious in women for the reduction of heart attacks. They also raised the possibility that women are more susceptible to aspirin resistance.
No comments:
Post a Comment